CPC C07K 16/2869 (2013.01) [A61K 39/39533 (2013.01); A61K 39/00 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/21 (2013.01); C07K 2317/32 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C12N 5/10 (2013.01); C12N 15/00 (2013.01); C12N 15/63 (2013.01); G01N 33/53 (2013.01)] | 12 Claims |
1. A method of making an antibody that selectively inhibits human CGRP receptor as compared with human AM1, AM2, and AMY1 receptors, comprising
administering to an animal an immunogen comprising:
(i) a soluble CGRP receptor, wherein the soluble CGRP receptor is a heterodimer comprising the N-terminal extracellular domain (ECD) of human CRLR polypeptide and the ECD of human RAMP1 polypeptide,
(ii) whole cells expressing full-length human CRLR and human RAMP1 polypeptides, or
(iii) membrane extracts of the cells in (ii);
recovering antibodies from the immunized animal that bind to both human CRLR polypeptide and human RAMP1 polypeptide in the human CGRP receptor; and
selecting monoclonal antibodies that bind to an epitope formed from amino acid residues from both human CRLR polypeptide and human RAMP1 polypeptide in the human CGRP receptor.
|